Provention Bio, Inc.

Sanofi has high hopes for its anti-CD3 antibody therapy, Tzield, in delaying the progression of type 1 diabetes but despite achieving its primary biomarker goal, its latest Phase III has fallen short

Biogen, Inc. was part of a close bidding war against another big pharma firm, believed to be Sanofi , prior to its $7.3bn acquisition of rare disease specialist Reata Pharmaceuticals, Inc. last mo

Privately held Recludix Pharma debuted in 2021 with a $60m series A financing to back its theory for targeting the SH2 domain of the signal transducer and activator of transcription (STAT) protein f

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic